WO1996040187A1 - Surface-modifying copolymers having cell adhesion properties - Google Patents

Surface-modifying copolymers having cell adhesion properties Download PDF

Info

Publication number
WO1996040187A1
WO1996040187A1 PCT/US1996/007500 US9607500W WO9640187A1 WO 1996040187 A1 WO1996040187 A1 WO 1996040187A1 US 9607500 W US9607500 W US 9607500W WO 9640187 A1 WO9640187 A1 WO 9640187A1
Authority
WO
WIPO (PCT)
Prior art keywords
poly
additive
urethane
modifying
gly
Prior art date
Application number
PCT/US1996/007500
Other languages
French (fr)
Inventor
Judy S. Riffle
Original Assignee
Thoratec Laboratories Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thoratec Laboratories Corporation filed Critical Thoratec Laboratories Corporation
Priority to JP50068797A priority Critical patent/JP2001516228A/en
Priority to DE69612267T priority patent/DE69612267T2/en
Priority to CA002197000A priority patent/CA2197000C/en
Priority to AU58025/96A priority patent/AU5802596A/en
Priority to EP96914755A priority patent/EP0779815B1/en
Publication of WO1996040187A1 publication Critical patent/WO1996040187A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
    • A61L33/0076—Chemical modification of the substrate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G77/00—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule
    • C08G77/42—Block-or graft-polymers containing polysiloxane sequences
    • C08G77/458—Block-or graft-polymers containing polysiloxane sequences containing polyurethane sequences

Definitions

  • the present invention is directed to novel block copolymers which are hemocompatible surface-modifying additives for modifying polyurethane, poly (urethane urea), polystyrene or polystyrene-containing elastomer substrates.
  • Cell adhesion to natural or synthetic substrates is mediated by the interaction of cell adhesion proteins which correspondingly accommodate cell surface receptors.
  • Cell adhesion proteins are exemplified by fibronectin,
  • RGDS is one of the sequences found in fibronectin, fibrinogen and von Willebrand factor which aids adhesion to cells.
  • Fibronectin also contains RGDX-like adhesion sequences such as REDV (Arg-Glu-Asp-Val).
  • Biomaterial surfaces comprising either hydrophilic (e.g., polyethylene oxide) or extremely hydrophobic (e.g.,
  • polydimethylsiloxane are known in medical devices and are the subject of ongoing investigation for such cardiovascular applications, but such biomaterials are not as
  • the present invention provides nonpolar
  • polydimethylsiloxane blocks incorporated into a block copolymer onto which is covalently linked a particular chemical sequence for increased cell adhesion.
  • the nonpolar polydimethylsiloxane blocks selectively segregate toward the air interface of the substrate polymer surface as a result of the thermodynamic driving force to minimize surface free energy.
  • the cell adhesion sequence covalently linked thereto will also be pulled toward the surface of the polymer films by virtue of the fact that they are covalently bound to the polydimethylsiloxane.
  • the copolymers can either be blended with substrate polymers in low amounts, coated onto substrate polymers in low amounts, or covalently attached to the substrate polymers. When placed in contact with blood, the cell adhesion amino acid sequences will rise to the surface in the hydrophilic environment, and
  • endothelial tissue unique to the individual in which the device is implanted will grow over the
  • biomaterial surface and blood will not coagulate on this surface. Since only the surface of the biomaterial will expose the polydimethylsiloxane-amino acid copolymers, a variety of bulk polymeric substrates may be used which have a wide range of mechanical and morphological properties.
  • the copolymers of the present invention will comprise at least three blocks or segments, each with a specific function, that is, an anchor block, a surface active block and the amino acid sequence. There may be an optional short hydrophilic spacer between the hydrophobic polydimethylsiloxane surface active block and the amino acid sequence.
  • the function of the anchor block will be to provide the ability to form a film so that the copolymer will not be extracted from the biomaterial surface in the presence of blood, and to provide compatibility with the bulk material. This is an important feature in view of regulatory concerns.
  • the anchor block must be chemically compatible with the bulk of the biomaterial substrate.
  • copolymers with polystyrene anchor blocks will be suitable for blending with or coating onto polystyrene, polystyrene containing elastomers, or polyphenylene oxide.
  • Copolymers containing either polyurethane or polyurea segments would be suitable for blending with polyurethane, polyurea, or poly (urethane-urea) bulk materials.
  • a short, hydrophilic, spacer such as poly (2- ethyloxazoline) or poly (ethylene oxide) can be inserted between the polydimethylsiloxane and the amino acid
  • segment By the term block it is meant that there is one type of recurring unit .
  • block is a generic term, the term “segment” is sometimes used in the art to represent a relatively short length of repeating units, e.g., less than about ten monomeric units, but preferably less than 3 monomeric units, typically
  • Block copolymers or segmented copolymers are composed of at least two blocks, one block composed of one type of recurring unit and at least one other block composed of a different type of recurring unit.
  • Block copolymers as defined herein may be linear, cyclic or branched (cross- linked) structures.
  • the preferred block copolymers in accordance with the present invention are linear.
  • the block copolymers according to the present invention are hemo-compatible surface-modifying copolymer additives having the formulas:
  • A is a poly (urethane), poly (urethane-urea), or polystyrene hard block
  • B is a polysiloxane hydrophobic soft-block
  • C is an optional hydrophilic spacer
  • D is peptide sequence selected from the group consisting of:
  • X and X' are any amino acid; and each n, v, m, and p is independently an integer greater than 0 up to about 500.
  • the preferred amino acid for X and X' is Gly.
  • the hard block (A) need not be a poly (urethane) or poly (urethane urea), as long as it is a hard block which is thermodynamically miscible with a poly (urethane), or poly
  • the hard block need not be a Polystyrene, as long as it is a hard block which is miscible with a polystyrene or polystyrene-containing base polymer.
  • Copolymers containing the anchor block and the surface-active block can be made in a variety of ways.
  • the anchor block is polystyrene an activated terminus polystyrene may be prepared and then reacted with a cyclic siloxane to produce a copolymer of the anchor block (polystyrene) and the surface active block (polysiloxane) .
  • the copolymer can then be reacted with an amino acid sequence.
  • the polystyrene polysiloxane copolymer can be end-capped with activated ethyloxazoline groups for reaction with the peptide.
  • the methylene chloride-terminated polystyrene polysiloxane copolymer is treated with ethyloxazoline to make the ethyloxazoline-terminated intermediates, which after treatment with the peptide GRGD, results in the peptide-terminated copolymer.
  • hydroxy functional dimethylsiloxane end-blocking reagents may be prepared whereby the molecular weight of polydimethylsiloxane oligomers can be controlled by synthetic conditions.
  • polysiloxane-urethane blocked polymers may be prepared modified with appended peptide moieties (such as RGD) which are covalently linked to the polysiloxane portion of the chain via an arginine N- terminal.
  • Cyclosiloxanes having functional substituents such as cyanopropyl in addition to methyl attached to the silicon atoms can be polymerized with the D 4 to prepare analogous siloxane oligomers with pendent functional groups along the oligomer backbone.
  • the yield of the desired polymer is sensitive to the size of the substituent group on the silicon atoms in the siloxane system whereby the yield decreases for hydrogen, alkyl groups, and
  • a polyurethane copolymer backbone with pendent benzyl butyrate substituents may be synthesized in a manner similar to the methods used for preparing block copolymers.
  • Polysiloxane prepolymers may be end-capped by reaction with an excess of methylene diphenyldiisocyanate and then extended with 1, 4-butanediol.
  • the benzyl esters may be removed by known methods, such as by hydrogenation. This is shown in scheme 5, below.
  • the peptides containing the amino acid segments such as RGD may be prepared by known procedures such as that shown in scheme 6. h d
  • amine terminus of these graft segments may be deblocked and the grafts bonded to the pendent carboxypropyl units on a block copolymer using dicyclohexyl carbodiimide as an activating agent as shown in scheme 7.
  • Polyethylene oxide spacers can be added to the amine
  • Scheme 9 Preparation of polyethylene oxide spacers with an amine terminus and with a carboxylic acid terminus.
  • the starting material is preferrably the p-nitro-phenoxide salt.
  • This oligomeric group may be appended to the carboxyl group on the siloxane portion of the copolymer by coupling the amine terminus to the PEO unit as shown in scheme 10.
  • spacers may be utilized such as poly(aolkyloxazoline), polyacrylamides, polylvinylpyrrolidone).
  • poly(aolkyloxazoline), polyacrylamides, polylvinylpyrrolidone) poly(aolkyloxazoline), polyacrylamides, polylvinylpyrrolidone).
  • polyethylene oxide spacers or other polyalkylene oxide spacers are preferred since the binding strength to hydrogen bonding surfaces of ether oxygens is expected to be less than the binding strength of the amino bonds of the amino acid segments. Therefore, the polyethylene oxide spacers would not
  • vinylacetic acid can either be coupled directly to benzylalcohol using known activating agents (e.g. dicyclohexylcarbodiimide), or it can first be converted to the corresponding acid chloride and
  • this siloxane tetramer can then be equilibrated with D4 and siloxane hydroxy terminated monomers to form the hydroxy functional terminated polysiloxane oligomers with pendent protected carboxy groups.
  • Scheme 6 there is shown a conventional Merrifield synthesis scheme for coupling amino acids to make the peptide RGD.
  • Scheme 9 there is shown the preparation of polyethylene oxide spacers having an amine terminus and a carboxylic acid terminus.
  • Scheme 7 there is shown the addition of the protected peptides to the carboxy terminal pendant groups of hydroxy functional polysiloxane oligomers and then removal of the protecting groups to form, in this case, a
  • polymers according to the present invention are useful for surface modification of base polymers which are poly (urethane), poly (urethane-urea) s , polystyrenes or polystyrene-containing elastomers, to allow endothelial cell adhesion thereto, thereby forming endothelial monolayers which are nonthrombogenic.
  • base polymers which are poly (urethane), poly (urethane-urea) s , polystyrenes or polystyrene-containing elastomers, to allow endothelial cell adhesion thereto, thereby forming endothelial monolayers which are nonthrombogenic.
  • base polymers which are poly (urethane), poly (urethane-urea) s , polystyrenes or polystyrene-containing elastomers, to allow endothelial cell adhesion thereto, thereby forming endothelial monolayers which are nonthrombogenic.
  • the base polymer modified according to the present invention may be used in blood-contacting devices, such as vascular
  • prostheses in the venous or arterial system heart patches, heart valves, as the outer encapsulants of implantable devices such as pacemakers, catheters or the outer sheath of catheters in contact with body fluids, temporary coverings on open wounds.
  • the surface may also be utilized in
  • extracorporeal devices to provide channels through which body fluids may be passed in heart, lung and kidney

Abstract

A hemocompatible surface-modifying additive is provided for modifying polyurethane or polyurethane-urea substrates. The additive has a polyurethane or polyurethane urea hard block or an alternative block which is miscible with the poly(urethane) or poly(urethane-urea) base polymer, a polysiloxane hydrophobic soft block, an optional hydrophilic spacer and a peptide selected from the group consisting of Arg-Gly-Asp, X-Arg-Gly-Asp, Arg-Gly-Asp-X and X-Arg-Gly-Asp-X', wherein X and X' are amino acids.

Description

SURFACE-MODIFYING COPOLYMERS
HAVING CELL ADHESION PROPERTIES Field of the Invention
The present invention is directed to novel block copolymers which are hemocompatible surface-modifying additives for modifying polyurethane, poly (urethane urea), polystyrene or polystyrene-containing elastomer substrates. Background of the Invention
Cell adhesion to natural or synthetic substrates is mediated by the interaction of cell adhesion proteins which correspondingly accommodate cell surface receptors. Cell adhesion proteins are exemplified by fibronectin,
vibronectin, collagen, thrombospondin, von Willebrand factor and laminin, all found in the extracellular matrix. These call adhesion proteins have cell surface receptors having varying specificity depending on the particular receptor. In many cases the cell binding sequences within the cell adhesion proteins which comprise part of the receptor consist of variants of the sequence RGDX (where x is a variant amino acid) (RGDX equals Arg-Gly-Asp-X). For example, RGDS is one of the sequences found in fibronectin, fibrinogen and von Willebrand factor which aids adhesion to cells. Fibronectin also contains RGDX-like adhesion sequences such as REDV (Arg-Glu-Asp-Val). Since the sequences within the cell adhesion proteins appear to be responsible for cell adhesion, there have been studies of the binding capacity of these particular short sequences when they are not within the context of the larger protein. For example, J.A. Hubbell et al., Bio/Technology, 1991, 9., 568-571, and Annals of the NY Academy of Sciences, 665, 1992, 253-258, disclosed a study of cell and blood platelet binding activity onto surfaces with covalently attached RGD amino acid sequences . These sequences supported the
spreading and growth of human fibroblasts, human vascular smooth muscle cells and human umbilical cord endothelial cells, but did not support the spreading of blood platelets. Sequences containing REDV attached in the same manner specifically supported the spreading and growth of human umbilical cord endothelial cells but also did not support the spreading of blood platelets.
Accordingly, there is a need to develop synthetic biomaterials for applications in the human cardiovascular system which will resist blood coagulation by promoting the growth of protective endothelial layers over the surfaces but yet which would also mediate the buildup of thrombus. Biomaterial surfaces comprising either hydrophilic (e.g., polyethylene oxide) or extremely hydrophobic (e.g.,
polydimethylsiloxane) are known in medical devices and are the subject of ongoing investigation for such cardiovascular applications, but such biomaterials are not as
thromboresistant as endothelialized surfaces. Thus while it is currently possible to produce devices for relatively short-term functions while using anticoagulants to aid in preventing clotting, there are no suitable materials for lifetime applications.
The present invention provides nonpolar
polydimethylsiloxane blocks incorporated into a block copolymer onto which is covalently linked a particular chemical sequence for increased cell adhesion. The nonpolar polydimethylsiloxane blocks selectively segregate toward the air interface of the substrate polymer surface as a result of the thermodynamic driving force to minimize surface free energy. The cell adhesion sequence covalently linked thereto will also be pulled toward the surface of the polymer films by virtue of the fact that they are covalently bound to the polydimethylsiloxane. The copolymers can either be blended with substrate polymers in low amounts, coated onto substrate polymers in low amounts, or covalently attached to the substrate polymers. When placed in contact with blood, the cell adhesion amino acid sequences will rise to the surface in the hydrophilic environment, and
selectively bind endothelial cells and will not bind blood platelets. Thus endothelial tissue unique to the individual in which the device is implanted will grow over the
biomaterial surface and blood will not coagulate on this surface. Since only the surface of the biomaterial will expose the polydimethylsiloxane-amino acid copolymers, a variety of bulk polymeric substrates may be used which have a wide range of mechanical and morphological properties.
Summary of the Invention
The copolymers of the present invention will comprise at least three blocks or segments, each with a specific function, that is, an anchor block, a surface active block and the amino acid sequence. There may be an optional short hydrophilic spacer between the hydrophobic polydimethylsiloxane surface active block and the amino acid sequence. The function of the anchor block will be to provide the ability to form a film so that the copolymer will not be extracted from the biomaterial surface in the presence of blood, and to provide compatibility with the bulk material. This is an important feature in view of regulatory concerns. The anchor block must be chemically compatible with the bulk of the biomaterial substrate. For example, copolymers with polystyrene anchor blocks will be suitable for blending with or coating onto polystyrene, polystyrene containing elastomers, or polyphenylene oxide. Copolymers containing either polyurethane or polyurea segments would be suitable for blending with polyurethane, polyurea, or poly (urethane-urea) bulk materials.
Alternatively, a short, hydrophilic, spacer such as poly (2- ethyloxazoline) or poly (ethylene oxide) can be inserted between the polydimethylsiloxane and the amino acid
sequence.
Brief Description of the Drawing
Description of the Preferred Embodiments The copolymers provided in accordance with the present invention comprise at least three blocks or
segments . By the term block it is meant that there is one type of recurring unit . Although the term block is a generic term, the term "segment" is sometimes used in the art to represent a relatively short length of repeating units, e.g., less than about ten monomeric units, but preferably less than 3 monomeric units, typically
alternating more than once with structural formulas such as ABAB. Block copolymers or segmented copolymers are composed of at least two blocks, one block composed of one type of recurring unit and at least one other block composed of a different type of recurring unit. Block copolymers as defined herein may be linear, cyclic or branched (cross- linked) structures. The preferred block copolymers in accordance with the present invention are linear. The block copolymers according to the present invention are hemo-compatible surface-modifying copolymer additives having the formulas:
Figure imgf000007_0001
wherein A is a poly (urethane), poly (urethane-urea), or polystyrene hard block; B is a polysiloxane hydrophobic soft-block; C is an optional hydrophilic spacer; and D is peptide sequence selected from the group consisting of:
Arg-Gly-Asp, X-Arg-Gly-Asp, Arg-Gly-Asp-X and
X'-Arg-Gly-Asp-X wherein X and X' are any amino acid; and each n, v, m, and p is independently an integer greater than 0 up to about 500. The preferred amino acid for X and X' is Gly.
The hard block (A) need not be a poly (urethane) or poly (urethane urea), as long as it is a hard block which is thermodynamically miscible with a poly (urethane), or poly
(urethane urea) base polymer. Likewise, the hard block need not be a Polystyrene, as long as it is a hard block which is miscible with a polystyrene or polystyrene-containing base polymer.
Copolymers containing the anchor block and the surface-active block can be made in a variety of ways. For example, if the anchor block is polystyrene an activated terminus polystyrene may be prepared and then reacted with a cyclic siloxane to produce a copolymer of the anchor block (polystyrene) and the surface active block (polysiloxane) . The copolymer can then be reacted with an amino acid sequence.
An exemplary scheme is shown below. In scheme 1 sec-butyl-lithium is reacted with styrene to produce an alkyl lithium terminated polystyrene. This in turn is reacted with cyclic polysiloxane then capped with a silane having an activated terminal (in this case, chloromethyl) for further reaction.
Figure imgf000008_0001
In scheme 2 the terminal chloromethyl group is converted to an iodomethyl group then treated with the peptide.
Figure imgf000009_0001
Alternatively, the polystyrene polysiloxane copolymer can be end-capped with activated ethyloxazoline groups for reaction with the peptide. Referring below to scheme 3, the methylene chloride-terminated polystyrene polysiloxane copolymer is treated with ethyloxazoline to make the ethyloxazoline-terminated intermediates, which after treatment with the peptide GRGD, results in the peptide-terminated copolymer.
Figure imgf000010_0001
) Alternatively, hydroxy functional dimethylsiloxane end-blocking reagents may be prepared whereby the molecular weight of polydimethylsiloxane oligomers can be controlled by synthetic conditions. Thus polysiloxane-urethane blocked polymers may be prepared modified with appended peptide moieties (such as RGD) which are covalently linked to the polysiloxane portion of the chain via an arginine N- terminal.
A preferred group of hydroxy-terminated oligomeric precursors is described below in scheme 4. (See U.S. Patent 4,689,383 to J.S. Riffle & R.S. Ward, 1987.)
Figure imgf000011_0001
Scheme 4: Preparation of hydroxyfunctional dimethylsiloxane endblocking reagent (I), and controlled molecular weight polydimethylsiloxane oligomers with hydroxyl endgroups. A polydimethylsiloxane is reacted with an epoxy allyl ether to form the epoxy-terminated siloxane. The epoxy end groups are then opened with methanol and then coequilibration is used to create oligomers of desired molecular weight ranges using D4, a cyclosiloxane tetramer. Cyclosiloxanes having functional substituents such as cyanopropyl in addition to methyl attached to the silicon atoms can be polymerized with the D4 to prepare analogous siloxane oligomers with pendent functional groups along the oligomer backbone. The yield of the desired polymer is sensitive to the size of the substituent group on the silicon atoms in the siloxane system whereby the yield decreases for hydrogen, alkyl groups, and
trifluoromethylpropyl as the substituents increase in size. However, a cyanopropyl-methylcyclotetrasiloxane yields a high volume fraction of polymer (about 75% when equilibrated with trifluoromethanesulfonic acid catalyst) .
A polyurethane copolymer backbone with pendent benzyl butyrate substituents may be synthesized in a manner similar to the methods used for preparing block copolymers. Polysiloxane prepolymers may be end-capped by reaction with an excess of methylene diphenyldiisocyanate and then extended with 1, 4-butanediol. The benzyl esters may be removed by known methods, such as by hydrogenation. This is shown in scheme 5, below.
Figure imgf000013_0001
Scheme 5: Siloxane cyclic tetramer with protected
carboxylic acid functionality.
The peptides containing the amino acid segments such as RGD, may be prepared by known procedures such as that shown in scheme 6. h d
r
Figure imgf000014_0001
The amine terminus of these graft segments may be deblocked and the grafts bonded to the pendent carboxypropyl units on a block copolymer using dicyclohexyl carbodiimide as an activating agent as shown in scheme 7.
Figure imgf000015_0001
Scheme 7 : Attachment to RGD segments to the polymer backbone The remaining benzyl ester protecting groups on the aspartic acid may be deprotected by hydrogenation. Deprotection reactions conducted in the presence of the acid liable siloxane bonds may be achieved using hydrogenation, as opposed to acid hydrolysis, to ensure that the copolymer backbone remains unaffected.
As an alternative to the last step in scheme 4, the following process (shown in scheme 8) may be utilized to prepare hydroxy-functional polysiloxane oligomers with pendent protected carboxy groups.
Figure imgf000016_0001
Scheme 8: Preparation of hydroxy functional polysiloxane oligomers with pendent protected carboxy groups. Due to the mechanism of equilibration reactions, the sequence of "x" and "y" units will be randomly distributed along the chain. The sequences of the repeat units indicated with subscripts x and y are randomly distributed along the chain.
Polyethylene oxide spacers can be added to the amine
terminal of the arginine residue via the method outlined in schemes 9 and 11 using protein synthesis techniques
(Merrifield method) to produce - PEO-RGD pendent groups.
Figure imgf000017_0001
Scheme 9: Preparation of polyethylene oxide spacers with an amine terminus and with a carboxylic acid terminus. The starting material is preferrably the p-nitro-phenoxide salt.
Figure imgf000018_0001
Scheme 11: Preparation of RGD segments with hydrophilic PEO spacer units.
This oligomeric group may be appended to the carboxyl group on the siloxane portion of the copolymer by coupling the amine terminus to the PEO unit as shown in scheme 10.
Figure imgf000019_0001
Scheme 10: Polysiloxane-urethane block copolymers
containing pendent amino acids appended via hydrophilic spacers.
It will be realized that other types of spacers may be utilized such as poly(aolkyloxazoline), polyacrylamides, polylvinylpyrrolidone). However, the polyethylene oxide spacers or other polyalkylene oxide spacers are preferred since the binding strength to hydrogen bonding surfaces of ether oxygens is expected to be less than the binding strength of the amino bonds of the amino acid segments. Therefore, the polyethylene oxide spacers would not
substantially interfere with the binding process of the amino acids to the cell surfaces. Referring to Scheme 5, vinylacetic acid can either be coupled directly to benzylalcohol using known activating agents (e.g. dicyclohexylcarbodiimide), or it can first be converted to the corresponding acid chloride and
subsequently esterified to form benzyl vinylacetate, and then is reacted with dichloromethylsilane to produce benzyl butyrate silane. This is then converted to the cyclic siloxane tetramer having protected carboxylic acid
functionalities. Referring to Scheme 8, this siloxane tetramer can then be equilibrated with D4 and siloxane hydroxy terminated monomers to form the hydroxy functional terminated polysiloxane oligomers with pendent protected carboxy groups. Referring to Scheme 6 there is shown a conventional Merrifield synthesis scheme for coupling amino acids to make the peptide RGD. Referring to Scheme 9 there is shown the preparation of polyethylene oxide spacers having an amine terminus and a carboxylic acid terminus. Referring to Scheme 7 there is shown the addition of the protected peptides to the carboxy terminal pendant groups of hydroxy functional polysiloxane oligomers and then removal of the protecting groups to form, in this case, a
polyurethane polysiloxane polymer backbone having pendent RGD groups. Referring to Scheme 11 there is shown the attachment of the PEO spacers to the amino terminus of the RGD end of the RGD peptide.
It will be realized that other linear polymers may be utilized such as polysiloxane-polylactone block
copolymers, examples of which are described in Patent No. 4,663,413 incorporated herein by reference. Methods of preparation of dihydroxy functional polydimethylsiloxane oligomers are further disclosed in Patent No. 4,689,383, incorporated herein by reference. The polymers according to the present invention are useful for surface modification of base polymers which are poly (urethane), poly (urethane-urea) s , polystyrenes or polystyrene-containing elastomers, to allow endothelial cell adhesion thereto, thereby forming endothelial monolayers which are nonthrombogenic. Typically, the polymers
according to the present invention may be utilized as additives to the poly (urethane), poly (urethane-urea), polystyrene, or polystyrene-containing elastomer base polymer in amounts of 0.1 to 20 percent by weight. The base polymer modified according to the present invention may be used in blood-contacting devices, such as vascular
prostheses in the venous or arterial system, heart patches, heart valves, as the outer encapsulants of implantable devices such as pacemakers, catheters or the outer sheath of catheters in contact with body fluids, temporary coverings on open wounds. The surface may also be utilized in
extracorporeal devices to provide channels through which body fluids may be passed in heart, lung and kidney
machines.

Claims

1. A hemocompatible surface-modifying copolymer additive for modifying poly(urethane) or poly(urethane urea) substrates, said additive having the formulas
Figure imgf000022_0001
wherein A is a polyurethane or poly(urethane urea) hard block or an alternative block which is thermodynamically miscible with the poly(urethane) or poly(urethane-urea) base polymer. B is a polysiloxane hydrophobic soft block; C is an optional hydrophilic spacer; D is a peptide selected from the group consisting of the sequence -Arg-Gly-Asp and -X- Arg-Gly-Asp, wherein X is an amino acid; and n, v, m and p are each independently an integer greater than 0 to 100.
2. An additive according to Claim 1 wherein X is Gly.
3. An additive according to Claim 1 wherein said spacer is a polyalkylene oxide.
4. An additive according to Claim 1 wherein said additive is of the formula
Figure imgf000022_0002
5. An additive according to Claim 1 wherein said additive is of the formula
Figure imgf000023_0003
6. An additive according to Claim 1 wherein said additive is of the formula
Figure imgf000023_0001
7. An additive according to Claim 1 wherein said additive is of the formula
Figure imgf000023_0002
8. A blood-contacting device comprising a blood- contacting surface of a base polymer and an additive of the formula:
Figure imgf000023_0004
or mixtures of two or more different additives of said formulas.
9. A method of modifying a poly (urethane) substrate to impart a hemocompatible surface thereto, according to Claim 1 of the formula:
or mixtures of two or more different additives of said formulas.
9. A method of modifying a poly(urethane) substrate to impart a hemocompatible surface thereto, comprising the step of incorporating into said substrate an effective hemocompatible surface-active amount of an additive according to any one of Claims 1 through 7.
10. A method of modifying a poly(urethane urea) substrate to impart a hemocompatible surface thereto, comprising the step of incorporating into said substrate an effective hemocompatible surface-active amount of an additive according to any one of Claims 1 through 7.
PCT/US1996/007500 1995-06-07 1996-05-22 Surface-modifying copolymers having cell adhesion properties WO1996040187A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP50068797A JP2001516228A (en) 1995-06-07 1996-05-22 Cell adhesive surface modified copolymer
DE69612267T DE69612267T2 (en) 1995-06-07 1996-05-22 SURFACE MODIFYING COPOLYMERS HAVING CELL ADHESION PROPERTIES
CA002197000A CA2197000C (en) 1995-06-07 1996-05-22 Surface-modifying copolymers having cell adhesion properties
AU58025/96A AU5802596A (en) 1995-06-07 1996-05-22 Surface-modifying copolymers having cell adhesion properties
EP96914755A EP0779815B1 (en) 1995-06-07 1996-05-22 Surface-modifying copolymers having cell adhesion properties

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/487,604 1995-06-07
US08/487,604 US5733538A (en) 1995-06-07 1995-06-07 Surface-modifying copolymers having cell adhesion properties

Publications (1)

Publication Number Publication Date
WO1996040187A1 true WO1996040187A1 (en) 1996-12-19

Family

ID=23936420

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/007500 WO1996040187A1 (en) 1995-06-07 1996-05-22 Surface-modifying copolymers having cell adhesion properties

Country Status (8)

Country Link
US (1) US5733538A (en)
EP (1) EP0779815B1 (en)
JP (1) JP2001516228A (en)
AU (1) AU5802596A (en)
CA (1) CA2197000C (en)
DE (1) DE69612267T2 (en)
ES (1) ES2155188T3 (en)
WO (1) WO1996040187A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262287B1 (en) * 1997-05-15 2001-07-17 Givaudan-Roure (International) Sa Fragrance precursor compounds
EP1959971A2 (en) * 2005-12-08 2008-08-27 The Polymer Technology Group, Inc. Self-assembling monomers and oligomers as surface-modifying endgroups for polymers

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548263B1 (en) 1997-05-29 2003-04-15 Cellomics, Inc. Miniaturized cell array methods and apparatus for cell-based screening
US6136872A (en) * 1998-11-20 2000-10-24 Shell Oil Company Freeze-dried polystyrene-polysiloxane foams
AUPQ100699A0 (en) 1999-06-17 1999-07-08 Northern Sydney Area Health Service An assist device for the failing heart
US6403063B1 (en) 1999-07-26 2002-06-11 Kenneth I. Sawyer Method of treating nail fungus
KR100312178B1 (en) * 1999-10-06 2001-11-03 서경배 the new amino acid silicon polymers, the method for producing them, the amino acid silicon polymer-suface treated cosmetic particles, and the cosmetic composition including the above particles
US6942873B2 (en) 2000-09-25 2005-09-13 The Board Of Trustees Of The University Of Illinois Microfabrication of membranes containing projections and grooves for growing cells
AUPR333301A0 (en) * 2001-02-23 2001-03-22 Northern Sydney Area Health Service Determining the volume of a normal heart and its pathological and treated variants by using dimension sensors
US6783709B2 (en) * 2002-07-10 2004-08-31 The Regents Of The University Of California Self-healing organosiloxane materials containing reversible and energy-dispersive crosslinking domains
ATE374049T1 (en) * 2002-08-13 2007-10-15 Medtronic Inc SYSTEM FOR DELIVERING ACTIVE INGREDIENTS WITH A HYDROPHOBIC CELLULOSE DERIVATIVE
ATE459380T1 (en) * 2002-08-13 2010-03-15 Medtronic Inc DOSAGE SYSTEMS OF ACTIVE INGREDIENTS WITH POLY(ETHYLENE-CO(METH)ACRYLATES, MEDICAL DEVICE AND METHOD
WO2004014453A1 (en) * 2002-08-13 2004-02-19 Medtronic, Inc Medical device exhibiting improved adhesion between polymeric coating and substrate
EP1536846A1 (en) * 2002-08-13 2005-06-08 Medtronic, Inc. Active agent delivery system including a polyurethane, medical device, and method
AU2003258209A1 (en) * 2002-08-13 2004-02-25 Medtronic, Inc. Active agent delivery systems, medical devices, and methods
WO2004014448A1 (en) * 2002-08-13 2004-02-19 Medtronic, Inc. Active agent delivery system including a hydrophilic polymer, medical device, and method
GB0222522D0 (en) 2002-09-27 2002-11-06 Controlled Therapeutics Sct Water-swellable polymers
EP1684820A2 (en) * 2003-08-13 2006-08-02 Medtronic, Inc. Active agent delivery systems including a miscible polymer blend, medical devices, and methods
US20050095218A1 (en) * 2003-10-29 2005-05-05 The Procter & Gamble Company Personal care composition containing a detersive surfactant, an antidandruff component, and ketoamide surfactants
US8791073B2 (en) * 2004-05-14 2014-07-29 William Marsh Rice University Peptide-modified polyurethane compositions and associated methods
GB0417401D0 (en) 2004-08-05 2004-09-08 Controlled Therapeutics Sct Stabilised prostaglandin composition
US8084275B2 (en) * 2005-02-08 2011-12-27 Fujifilm Corporation Magnetic composite body, production method thereof, method for removing substance with mannose on its surface, and method for concentrating substance with mannose on its surface
JP2007040978A (en) * 2005-06-30 2007-02-15 Fujifilm Corp Method for separating objective element using magnetic nanoparticles
GB0613333D0 (en) 2006-07-05 2006-08-16 Controlled Therapeutics Sct Hydrophilic polyurethane compositions
GB0613638D0 (en) 2006-07-08 2006-08-16 Controlled Therapeutics Sct Polyurethane elastomers
GB0620685D0 (en) * 2006-10-18 2006-11-29 Controlled Therapeutics Sct Bioresorbable polymers
JP5062820B2 (en) * 2007-03-23 2012-10-31 株式会社Ａｄｅｋａ Cyclic siloxane compound and positive resist composition using the same
WO2013151755A1 (en) 2012-04-04 2013-10-10 University Of Washington Through Its Center For Commercialization Systems and method for engineering muscle tissue
EP2913067A4 (en) * 2012-10-26 2016-06-01 Jms Co Ltd Artificial blood vessel, and method for producing artificial blood vessel

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4789601A (en) * 1987-05-04 1988-12-06 Banes Albert J Biocompatible polyorganosiloxane composition for cell culture apparatus
US5324591A (en) * 1987-03-06 1994-06-28 Geo-Centers, Inc. Deep ultraviolet photolithographically defined ultra-thin films for selective cell adhesion and outgrowth and method of manufacturing the same and devices containing the same
US5330911A (en) * 1989-09-28 1994-07-19 Board Of Regents, The University Of Texas System Surfaces having desirable cell adhesive effects
US5369012A (en) * 1992-03-26 1994-11-29 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Method of making a membrane having hydrophilic and hydrophobic surfaces for adhering cells or antibodies by using atomic oxygen or hydroxyl radicals

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4689383A (en) * 1986-03-18 1987-08-25 Thoratec Laboratories Corp. Hydroxyl-functional disiloxanes and polysiloxane oligomers
US4822741A (en) * 1987-05-04 1989-04-18 Banes Albert J Biocompatible polyorganosiloxane composition for cell culture apparatus
US4839280A (en) * 1987-05-04 1989-06-13 Banes Albert J Apparatus for applying stress to cell cultures

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5324591A (en) * 1987-03-06 1994-06-28 Geo-Centers, Inc. Deep ultraviolet photolithographically defined ultra-thin films for selective cell adhesion and outgrowth and method of manufacturing the same and devices containing the same
US4789601A (en) * 1987-05-04 1988-12-06 Banes Albert J Biocompatible polyorganosiloxane composition for cell culture apparatus
US5330911A (en) * 1989-09-28 1994-07-19 Board Of Regents, The University Of Texas System Surfaces having desirable cell adhesive effects
US5369012A (en) * 1992-03-26 1994-11-29 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Method of making a membrane having hydrophilic and hydrophobic surfaces for adhering cells or antibodies by using atomic oxygen or hydroxyl radicals

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP0779815A4 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262287B1 (en) * 1997-05-15 2001-07-17 Givaudan-Roure (International) Sa Fragrance precursor compounds
EP1959971A2 (en) * 2005-12-08 2008-08-27 The Polymer Technology Group, Inc. Self-assembling monomers and oligomers as surface-modifying endgroups for polymers
EP1959971A4 (en) * 2005-12-08 2010-01-20 Polymer Technology Group Inc Self-assembling monomers and oligomers as surface-modifying endgroups for polymers
EP2213293A3 (en) * 2005-12-08 2011-09-28 The Polymer Technology Group Incorporated Self-assembling monomers and oligomers as surface-modifying endgroups for polymers

Also Published As

Publication number Publication date
EP0779815B1 (en) 2001-03-28
ES2155188T3 (en) 2001-05-01
CA2197000A1 (en) 1996-12-19
CA2197000C (en) 2003-10-21
JP2001516228A (en) 2001-09-25
US5733538A (en) 1998-03-31
DE69612267D1 (en) 2001-05-03
EP0779815A4 (en) 1998-06-03
DE69612267T2 (en) 2001-07-05
EP0779815A1 (en) 1997-06-25
AU5802596A (en) 1996-12-30

Similar Documents

Publication Publication Date Title
EP0779815B1 (en) Surface-modifying copolymers having cell adhesion properties
Park et al. PDMS-based polyurethanes with MPEG grafts: synthesis, characterization and platelet adhesion study
AU2010270610B2 (en) Amphiphilic silicone copolymers for pressure sensitive adhesive applications
Lin et al. Endothelial cell adhesion on polyurethanes containing covalently attached RGD-peptides
US4908404A (en) Synthetic amino acid-and/or peptide-containing graft copolymers
US5221724A (en) Polysiloxane polyurea urethanes
KR101054023B1 (en) Synthetic Matrix to Control Intracellular Proliferation and Tissue Regeneration
Lopez‐Donaire et al. Surface modifying oligomers used to functionalize polymeric surfaces: Consideration of blood contact applications
CA2567630A1 (en) Biological molecule-reactive hydrophilic silicone surface
JP2015507671A (en) Hydrophilic silicone gel adhesive
JP2011099106A (en) Zwitterionic group containing compound from michael-type reaction useful as monomer and macromer
AU2002363343A1 (en) Synthetic matrix for controlled cell ingrowth and tissue regeneration
Rutnakornpituk et al. Synthesis, characterization and properties of chitosan modified with poly (ethylene glycol)–polydimethylsiloxane amphiphilic block copolymers
EP0948370A1 (en) Process for preparing polyurethane-peo-heparin coating compositions
JPH09506012A (en) Multifunctional organic polymer
CA2349989A1 (en) Bioactive surface modifiers for polymers and articles made therefrom
JP2015506388A (en) Polymerizable hybrid polysiloxane and preparation
US20050063937A1 (en) Multiple-arm peptide compounds, methods of manufacture and use in therapy
JPS61181836A (en) Polysiloxane block copolymer
Ito et al. Design and synthesis of blood-compatible polyurethane derivatives
Gong et al. Hyaluronan immobilized polyurethane as a blood contacting material
EP0249416A2 (en) Method for modifying polymer surfaces with surface-active polymer blocks tethered to non-surface-active components
WO2021102151A1 (en) Multifunctional cyclic peptide polymer nanomaterials
Simonovsky et al. Synthesis of polyurethanes incorporating long alkyl side-chains with pendant carboxyl groups.
Duan Biomedical applications of dendrimer-modified polyurethanes with PEO (polyethylene oxide) attached.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML

WWE Wipo information: entry into national phase

Ref document number: 1996914755

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2197000

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 1997 500687

Country of ref document: JP

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 1996914755

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 1996914755

Country of ref document: EP